{
    "title": "A bill to amend title 38, United States Code, to provide for the establishment of Parkinson's Disease Research Education and Clinical Centers in the Veterans Health Administration of the Department of Veterans Affairs and Multiple Sclerosis Centers of Excellence.",
    "content": "SECTION 1. PARKINSON'S DISEASE RESEARCH, EDUCATION, CLINICAL CENTERS, \n              AND MULTIPLE SCLEROSIS CENTERS OF EXCELLENCE.\n\n    (a) Requirement for Establishment of Centers.--\n            (1) In general.--Subchapter II of chapter 73 of title 38, \n        United States Code, is amended by adding at the end the \n        following:\n``Sec. 7329. Parkinson's disease research, education, and clinical \n              centers and multiple sclerosis centers of excellence\n    ``(a) Designation.--The Secretary, upon the recommendation of the \nUnder Secretary for Health and pursuant to the provisions of this \nsection, shall--\n            ``(1) designate--\n                    ``(A) at least 6 Department health care facilities \n                as the locations for centers of Parkinson's disease \n                research, education, and clinical activities and \n                (subject to the appropriation of sufficient funds for \n                such purpose); and\n                    ``(B) at least 2 Department health care facilities \n                as the locations for Multiple Sclerosis Centers of \n                Excellence (subject to the appropriation of sufficient \n                funds for such purpose); and\n            ``(2) establish and operate such centers at such locations \n        in accordance with this section.\n    ``(b) Existing Facilities; Geographic Distribution.--In designating \nlocations for centers under subsection (a), the Secretary, upon the \nrecommendation of the Under Secretary for Health, shall--\n            ``(1) designate each Department health care facility that, \n        as of January 1, 2005, was operating a Parkinson's Disease \n        Research, Education, and Clinical Center or a Multiple \n        Sclerosis Center of Excellence unless the Secretary, on the \n        recommendation of the Under Secretary for Health, determines \n        that such facility--\n                    ``(A) does not meet the requirements of subsection \n                (c);\n                    ``(B) has not demonstrated effectiveness in \n                carrying out the established purposes of such center; \n                or\n                    ``(C) has not demonstrated the potential to carry \n                out such purposes effectively in the reasonably \n                foreseeable future; and\n            ``(2) assure appropriate geographic distribution of such \n        facilities.\n    ``(c) Minimum Requirements.--The Secretary may not designate a \nhealth care facility as a location for a center under subsection (a) \nunless--\n            ``(1) the peer review panel established under subsection \n        (d) determines that the proposal submitted by such facility is \n        among those proposals which meet the highest competitive \n        standards of scientific and clinical merit; and\n            ``(2) the Secretary, upon the recommendation of the Under \n        Secretary for Health, determines that the facility has (or may \n        reasonably be anticipated to develop)--\n                    ``(A) an arrangement with an accredited medical \n                school which provides education and training in \n                neurology and with which such facility is affiliated \n                under which residents receive education and training in \n                innovative diagnosis and treatment of chronic \n                neurodegenerative diseases and movement disorders, \n                including Parkinson's disease, or in the case of \n                Multiple Sclerosis Centers, multiple sclerosis disease;\n                    ``(B) the ability to attract the participation of \n                scientists who are capable of ingenuity and creativity \n                in health-care research efforts;\n                    ``(C) a policymaking advisory committee composed of \n                consumers and appropriate health care and research \n                representatives of the facility and of the affiliated \n                school or schools to advise the directors of such \n                facility and such center on policy matters pertaining \n                to the activities of such center during the period of \n                the operation of such center;\n                    ``(D) the capability to conduct effectively \n                evaluations of the activities of such center;\n                    ``(E) the capability to coordinate, as part of an \n                integrated national system, education, clinical, and \n                research activities within all facilities with such \n                centers;\n                    ``(F) the capability to jointly develop a \n                consortium of providers with interest in treating \n                neurodegenerative diseases, including Parkinson's \n                disease, and other movement disorders, or multiple \n                sclerosis in the case of Multiple Sclerosis Centers, at \n                facilities without such centers in order to ensure \n                better access to state of the art diagnosis, care, and \n                education for neurodegenerative disorders, or in the \n                case of Multiple Sclerosis Centers, autoimmune disease \n                affecting the central nervous system throughout the \n                health care system; and\n                    ``(G) the capability to develop a national \n                repository in the health care system for the collection \n                of data on health services delivered to veterans \n                seeking care for neurodegenerative diseases, including \n                Parkinson's disease, and other movement disorders, or \n                in the case of Multiple Sclerosis Centers, autoimmune \n                disease affecting the central nervous system.\n    ``(d) Panel.--(1) The Under Secretary for Health shall establish a \npanel to assess the scientific and clinical merit of proposals that are \nsubmitted to the Secretary for the establishment of new centers under \nthis section.\n    ``(2)(A) The membership of the panel shall consist of experts in \nneurodegenerative diseases, including Parkinson's disease and other \nmovement disorders, and, in the case of Multiple Sclerosis Centers, \nexperts in autoimmune disease affecting the central nervous system.\n    ``(B) Members of the panel shall serve as consultants to the \nDepartment for a period of no longer than 2 years except in the case of \npanelists asked to serve on the initial panel as specified in \nsubparagraph (C).\n    ``(C) In order to ensure panel continuity, half of the members of \nthe first panel shall be appointed for a period of 3 years and half for \na period of 2 years.\n    ``(3) The panel shall review each proposal submitted to the panel \nby the Under Secretary and shall submit its views on the relative \nscientific and clinical merit of each such proposal to the Under \nSecretary.\n    ``(4) The panel shall not be subject to the Federal Advisory \nCommittee Act.\n    ``(e) Adequate Funding.--Before providing funds for the operation \nof any such center at a health care facility other than a health care \nfacility designated under subsection (b)(1), the Secretary shall ensure \nthat--\n            ``(1) the Parkinson's disease center at each facility \n        designated under subsection (b)(1) is receiving adequate \n        funding to enable such center to function effectively in the \n        areas of Parkinson's disease research, education, and clinical \n        activities; and\n            ``(2) in the case of a new Multiple Sclerosis Center, that \n        existing centers are receiving adequate funding to enable such \n        centers to function effectively in the areas of multiple \n        sclerosis research, education, and clinical activities.\n    ``(f) Authorization of Appropriations.--(1) There are authorized to \nbe appropriated such sums as may be necessary for the support of the \nresearch and education activities of the centers established under \nsubsection (a).\n    ``(2) The Under Secretary for Health shall allocate to such centers \nfrom other funds appropriated generally for the Department medical \nservices account and medical and prosthetics research account, as \nappropriate, such amounts as the Under Secretary for Health determines \nappropriate.\n    ``(g) Funding Eligibility and Priority for Parkinson's Disease \nResearch.--Activities of clinical and scientific investigation at each \ncenter established under subsection (a) for Parkinson's disease shall--\n            ``(1) be eligible to compete for the award of funding from \n        funds appropriated for the Department medical and prosthetics \n        research account; and\n            ``(2) receive priority in the award of funding from such \n        account to the extent funds are awarded to projects for \n        research in Parkinson's disease and other movement disorders.\n    ``(h) Funding Eligibility and Priority for Multiple Sclerosis \nResearch.--Activities of clinical and scientific investigation at each \ncenter established under subsection (a) for multiple sclerosis shall--\n            ``(1) be eligible to compete for the award of funding from \n        funds appropriated for the Department medical and prosthetics \n        research account; and\n            ``(2) receive priority in the award of funding from such \n        account to the extent funds are awarded to projects for \n        research in multiple sclerosis and other movement disorders.''.\n            (2) Clerical amendment.--The table of sections at the \n        beginning of chapter 73 of title 38, United States Code, is \n        amended by inserting after the item relating to section 7328 \n        the following:\n\n``Sec. 7329. Parkinson's disease research, education, and clinical \n                            centers and multiple sclerosis centers of \n                            excellence.''.\n    (b) Effective Date.--Section 7329 of title 38, United States Code, \nas added by subsection (a), shall take effect on October 1, 2005."
}